Why we chose fibre-laser technology over the original Endolift^® device.

The moment the decision came up

Around 2022 we were rebuilding our energy-based device stack at Cosmedocs. Radiofrequency and microneedling RF were doing well for surface tightening, but a specific patient profile kept coming through the door — mid-thirties to mid-forties, low body fat, early jowl or sub-mental softening, and a very clear brief: "I don't want surgery, I don't want filler, I want the underlying structure tightened."

Intra-dermal laser fibre was the obvious category. The question was which platform. The name everyone knew was Endolift^® — Eufoton's 1470nm diode fibre system, launched in the mid-2010s, well-marketed in Italy and increasingly visible in London. So we did what any clinic should do before committing to a six-figure device purchase: we audited it against the alternatives.

What we actually evaluated

Three things drove the technology-fit review:

1. Chromophore selectivity vs the patient's real anatomy. 1470nm is water-selective and produces excellent collagen contraction — but it is not the wavelength you would choose if you were designing a device to remodel adipose tissue. For a patient whose jawline is being obscured by a soft sub-mental fat pocket, 1470nm alone leaves half the anatomical problem un-addressed.
2. The evidence base beyond the brand. 980nm diode has a decade-plus of peer-reviewed use in endovenous laser ablation (Proebstle, Almeida, Kabnick et al.) and laser lipolysis (Katz & McBean, Dermatol Surg 2008). It's not experimental. Combining it with 1470nm through a single fibre isn't a leap — it's an engineering convergence of two mature, separately validated wavelengths.
3. Delivery model and price transparency. The branded 1G route in the UK typically lands at £1,500–£3,500 per zone. When we mapped the true clinical cost — consumables, doctor time, review appointment — the honest number was closer to £450. A device choice that forced us to charge three times that would have compromised our transparent-pricing commitment.

Why "just buy the Endolift®" wasn't the safer answer

A reasonable challenge: if Endolift® is the established name, why take the harder route?Two reasons.

First, buying a branded 1G device would have meant delivering a treatment we knew was clinically narrower than what our audit patients needed. That is a subtle form of over-promise — telling a patient "yes, this will handle your jawline" when the platform can only really handle half the tissue in question. Under GMC Good Medical Practice, that kind of misalignment between claim and capability is exactly what we're meant to avoid.

Second, "safe" in aesthetic medicine isn't the same as "familiar". The safer route, clinically, is the one where the device does what the anatomy actually requires. Familiarity is a comfort for the clinic; anatomical fit is a benefit for the patient.

What the second-generation platform actually is

The platform we chose delivers 980nm and 1470nm through a single 200µm optical fibre, inserted through a fine cannula tract under topical and local anaesthesia. In practice that means:

• 1470nm handles collagen contraction and dermal tightening — the classical Endolift^® effect.
• 980nm handles adipose remodelling and small-vessel coagulation in the same pass.
• One insertion point per zone. No layered sessions to reach the fat layer separately.
• UKCA and CE-marked device — regulatory posture identical to any other UK-legal aesthetic laser.

We deliver this protocol as XL Endolaser. The name is ours; the underlying physics is drawn from two well-established diode-laser literatures.

The audit — what changed after 12 months

After a full year on the 2G platform we reviewed outcomes across our first cohort:

• Single-session sufficiency. ~82% of jawline / sub-mental patients did not need a second treatment within the following 12 months. On the 1G literature, comparable cohorts typically report 60–70% single-session sufficiency for the same anatomical brief.
• Downtime. Essentially unchanged — 2–3 days of visible swelling, minor bruising in a minority of patients. No increase in complication rate.
• Patient-reported outcome (POSAS / self-rated). Higher satisfaction on the "jawline definition" domain specifically, which is where the adipose channel does its work.
• Price point delivered. £450 per zone, stable, with no upward drift.

None of that says the 1G device is bad. It says the 2G platform mapped better onto the specific patient cohort we were treating.

What we won't claim

For clarity — and for trademark and ASA compliance — a short list of things we do not say:

• We do not say we perform Endolift^®. We don't. Endolift^® is a specific branded device by Eufoton s.r.l.
• We do not say XL Endolaser is "the same as" Endolift^®. It's the next generation of the same underlying idea — that's a different claim.
• We do not say 1G Endolift^® doesn't work. It does. Our position is about technology fit for our patient mix, not about denigrating a competitor's platform.

Who signs off on this decision

Every case at Cosmedocs is performed by a GMC-registered doctor. The laser-fibre lifting programme sits under my personal clinical accountability as Medical Director. I also serve as Lead Trainer for laser fibre lifting at the Harley Street Institute — the training body that credentials many of the doctors delivering this category of treatment across the UK. If the technology choice were wrong, I would be the first person accountable for it, both to my patients and to the profession.

The honest close

Choosing your platform is one of the least glamorous decisions a clinic makes. It happens years before the patient walks in, in a conference room with a spreadsheet, an audit and a shortlist. We chose fibre-laser over the branded 1G device because it fit our patient anatomy better, sat on a stronger combined evidence base, and let us deliver the treatment at a price that reflected its true clinical cost. Three years on, we'd make the same decision again.